BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

On May 29, Goldman Sachs analyst David Roman initiated coverage DexCom Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $104. The initiation is part of Goldman Sachs’s broader coverage ...

Aug 26 (Reuters) - Dexcom (DXCM.O), opens new tab said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. Stelo ...

Dexcom stock is drawing new interest from institutional investors while the FDA?s expanded clearance for the Stelo over-the-counter glucose biosensor highlights growth potential in continuous glucose ...

Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...

The company launched its Stelo continuous glucose monitor, or CGM. Stelo was developed to track blood sugar in real time for people with type 2 diabetes who don't require insulin treatment. But it ...

DexCom Inc. DXCM recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for ...